Nutropin AQ ( DrugBank: - )


3 diseases
告示番号疾患名(ページ内リンク)臨床試験数
78下垂体前葉機能低下症7
193プラダー・ウィリ症候群1
299嚢胞性線維症3

78. 下垂体前葉機能低下症


臨床試験数 : 494 薬物数 : 385 - (DrugBank : 49) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 100
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02311894
(ClinicalTrials.gov)
March 31, 20154/12/2014A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone DeficiencyA Phase IV, Multicenter, Open-Label Study of the Immunogenicity of Nutropin AQ® V1.1 [Somatropin (rDNA Origin) Injection] Administered Daily to Naïve Growth Hormone-Deficient Children (iSTUDY)Growth Hormone DeficiencyDrug: SomatropinGenentech, Inc.NULLCompleted3 Years14 YearsAll82Phase 4United States
2NCT01243892
(ClinicalTrials.gov)
November 201017/11/2010A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin DeviceA Phase IV, Open Label, Multicenter, Case-controlled Study of Growth in Patients Using the Nutropin AQ® Nuspin®Growth Hormone DeficiencyDevice: NuSpin;Drug: SomatropinGenentech, Inc.NULLTerminated2 Years14 YearsAll18Phase 4United States
3EUCTR2010-019735-35-FR
(EUCTR)
14/06/201030/04/2010Effets du traitement substitutif par hormone de croissance chez les patients présentant un déficit somatotrope sévère secondaire à un traumatisme crânienEffets du traitement substitutif par hormone de croissance chez les patients présentant un déficit somatotrope sévère secondaire à un traumatisme crânien Déficit somatotrope de l'adulte consécutif à un traumatisme crânien
MedDRA version: 12.1;Level: LLT;Classification code 10056438;Term: Growth hormone deficiency
Trade Name: Nutropin Aq
Product Name: NutropinAq
CHU AmiensNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
France
4NCT00837863
(ClinicalTrials.gov)
March 20092/2/2009Study of Weekly ALTU-238 Compared With Daily Nutropin AQ in Prepubertal Children With Growth Hormone DeficiencyA Twelve Month, Phase II, Randomized, Open-Label, Multi-Center, Dose-Ranging Study of Weekly ALTU-238 (Somatropin) as Compared With Daily Nutropin AQ (Somatropin) in Prepubertal Children With Growth Hormone DeficiencyGrowth Hormone DeficiencyDrug: SomatropinAltus PharmaceuticalsNULLRecruiting3 Years13 YearsBoth36Phase 2United States
5NCT00212758
(ClinicalTrials.gov)
January 200514/9/2005A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in BloodIGF-1 Generation Test in Children With Chronic Kidney DiseaseKidney Failure, Chronic;Growth Hormone DeficiencyDrug: Nutropin AQOregon Health and Science UniversityGenentech, Inc.Completed2 Years18 YearsAll17Phase 4United States
6NCT00140413
(ClinicalTrials.gov)
December 200431/8/2005Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve HypoplasiaEndocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve HypoplasiaGrowth Hormone Deficiency;Septo-Optic Dysplasia;HypopituitarismDrug: Nutropin AQChildren's Hospital Los AngelesGenentech, Inc.CompletedN/A5 YearsAll20Phase 4United States
7NCT00134420
(ClinicalTrials.gov)
February 200122/8/2005Growth Hormone and Chromosome 18q- and Abnormal GrowthGrowth Hormone Trial for Children With 18q- and Abnormal GrowthLoss of Chromosome 18q;Growth Hormone DeficiencyDrug: Nutropin AQ;Procedure: Arginine and Clonidine Stimulation Testing;Procedure: Growth Factors Laboratory Testing;Procedure: Neuropsychological TestingThe University of Texas Health Science Center at San AntonioSouth Texas Veterans Health Care System;Genentech, Inc.CompletedN/A18 YearsBoth20Phase 3United States

193. プラダー・ウィリ症候群


臨床試験数 : 111 薬物数 : 120 - (DrugBank : 30) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 103
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00444964
(ClinicalTrials.gov)
April 20056/3/2007Growth Hormone Use in Adults With Prader-Willi SyndromeGrowth Hormone Use in Adults With Prader-Willi SyndromePrader-Willi SyndromeDrug: Nutropin AQChildren's Mercy Hospital Kansas CityNULLRecruiting16 Years60 YearsBoth10Phase 3United States

299. 嚢胞性線維症


臨床試験数 : 1,696 薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00803179
(ClinicalTrials.gov)
November 20084/12/2008Growth Hormone Therapy for Wasting in Cystic FibrosisGrowth Hormone Therapy for Wasting in Cystic FibrosisCystic FibrosisDrug: Nutropin AQUniversity of Massachusetts, WorcesterNULLTerminated18 YearsN/AAll5Phase 1United States
2NCT00079742
(ClinicalTrials.gov)
September 200311/3/2004A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children With Cystic FibrosisA Phase II, Multicenter, Randomized, Controlled, Open-Label Study of the Safety and Efficacy of Nutropin AQ [Somatropin (DNA Origin) Injection] for the Treatment of Growth Restriction in Children With Cystic FibrosisCystic FibrosisDrug: Nutropin AQ [somatropin (DNA origin) injection]Genentech, Inc.NULLCompleted5 Years13 YearsBoth68Phase 2United States
3NCT00256555
(ClinicalTrials.gov)
February 200017/11/2005Growth Hormone Treatment Study in Children With Cystic FibrosisGROWTH HORMONE USE IN CYSTIC FIBROSIS - A MULTICENTER STUDYCystic FibrosisDrug: Nutropin AQUniversity of Texas Southwestern Medical CenterGenentech, Inc.Withdrawn5 Years12 YearsAll0Phase 2/Phase 3NULL